Complement 3 glomerulopathy
MONDO:0018013A rare primary membranoproliferative glomerulonephritis characterized by complement dysregulation occurring in the fluid phase and in the glomerular microenvironment, which results in prominent complement C3 deposition in kidney biopsy samples.
Also known as: C3 glomerulopathy, C3G, non-Ig-mediated MPGN, non-Ig-mediated membranoproliferative glomerulonephritis, non-immunoglobulin-mediated MPGN, non-immunoglobulin-mediated membranoproliferative glomerulonephritis
25 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New hope for rare kidney patients: Long-Term drug trial shows promise
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of a drug called iptacopan for people with two rare kidney diseases: C3 glomerulopathy and IC-MPGN. About 225 adults who have already completed a previous iptacopan study will take the drug for an extended period. The goa…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a targeted therapy tame rare kidney diseases in daily practice?
Disease control Recruiting nowThis study looks at how well the medication pegcetacoplan works and how safe it is for people with two rare kidney conditions: C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Researchers will follow about 150 patients who are…
Phase: PHASE4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Experimental drug aims to protect kidneys in inflammatory diseases
Disease control Recruiting nowThis study tests an experimental drug called ADX-097 in people aged 16 and older with three kidney conditions: IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The drug is given as an injection under the skin and is designed to reduce inflammation and protein leakage in t…
Phase: PHASE2 • Sponsor: Akebia Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for rare kidney disease? first human trial of CPV-104 begins
Disease control Recruiting nowThis study tests CPV-104, a new medicine designed to calm an overactive immune system part that attacks the kidneys in C3 glomerulopathy (C3G), a rare kidney disorder. It is the first time CPV-104 is given to people. The trial includes 39 participants: healthy volunteers receivin…
Phase: PHASE1 • Sponsor: eleva GmbH • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New siRNA drug aims to tame kidney disease
Disease control Recruiting nowThis Phase 2 study is testing a new drug called ADX-038 in 45 adults with complement-mediated kidney diseases, such as IgA nephropathy and C3G. The drug is an siRNA that targets the complement system, which is overactive in these conditions. Researchers are checking if it is safe…
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug combo aims to tame rare kidney diseases
Disease control Recruiting nowThis Phase 2 study tests a new drug called ADX-038, alone or with another drug (telitacicept), in 30 Chinese adults with kidney diseases caused by an overactive complement system (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the treatment is safe and can help control …
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug iptacopan aims to protect kidneys in rare C3G disease
Disease control Recruiting nowThis Phase 3 trial tests whether iptacopan can reduce protein in the urine and preserve kidney function in people with complement 3 glomerulopathy (C3G), a rare kidney disease. About 98 adults and adolescents will receive either iptacopan or a placebo for 6 to 12 months. The stud…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug fabhalta under Real-World watch in korea for rare blood and kidney diseases
Disease control Recruiting nowThis study is monitoring the safety and effectiveness of the drug iptacopan (Fabhalta) in 21 Korean adults with paroxysmal nocturnal hemoglobinuria (PNH) or C3 glomerulopathy (C3G). Researchers will track side effects and lab results from routine medical records. The goal is to s…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for rare blood and kidney diseases: iptacopan access program opens
Disease control AVAILABLEThis program provides early access to the drug iptacopan for people with serious or life-threatening C3 glomerulopathy (C3G) or paroxysmal nocturnal hemoglobinuria (PNH) who have no other treatment options. It is designed for patients who cannot join a clinical trial or have exha…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New pill CMS-D017 enters first human safety trials
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called CMS-D017 in 88 healthy adults to see if it is safe and how the body processes it. The drug is being developed for two rare conditions: paroxysmal nocturnal hemoglobinuria (a blood disorder) and complement-mediated kidney disease. Par…
Phase: PHASE1 • Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New ultrasound technique could spare kidney patients from biopsies
Knowledge-focused Recruiting nowThis study is testing a new ultrasound method to look at tiny blood vessels in the kidneys of people with nephritis (kidney inflammation). Researchers will use contrast-enhanced ultrasound and ultrasound localization microscopy to create detailed images of kidney blood flow. The …
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC